Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?
- PMID: 18571777
- DOI: 10.1002/ana.21391
Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?
Abstract
Objective: Mutations in the X-linked adrenoleukodystrophy (X-ALD) protein cause accumulation of unbranched saturated very-long-chain fatty acids, particularly in brain and adrenal cortex. In humans, the genetic defect causes progressive inflammatory demyelination in the brain, where very-long-chain fatty acids accumulate within phospholipid fractions such as lysophosphatidylcholine.
Methods: To address mechanisms of inflammation, we studied microglial activation in human ALD (10 autopsies) and lysophosphatidylcholine (C24:0) injection into the parietal cortex of mice.
Results: Unexpectedly, we found a zone lacking microglia within perilesional white matter, immediately beyond the actively demyelinating lesion edge. Surrounding this zone we observed clusters of activated and apoptotic microglia within subcortical white matter. Lysophosphatidylcholine (C24:0) injection in mice led to widespread microglial activation and apoptosis.
Interpretation: Our data suggest that the distinct mononuclear phagocytic cell response seen in cerebral X-ALD results, at least in part, from aberrant signaling to cognate receptors on microglia. Our findings support a hypothesis that microglial apoptosis in perilesional white matter represents an early stage in lesion evolution and may be an appropriate target for intervention in X-ALD patients with evidence of cerebral demyelination.
Similar articles
-
Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency.Acta Neuropathol. 2007 Dec;114(6):573-86. doi: 10.1007/s00401-007-0288-4. Epub 2007 Sep 9. Acta Neuropathol. 2007. PMID: 17828604
-
Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients.Neurobiol Dis. 2000 Dec;7(6 Pt B):600-12. doi: 10.1006/nbdi.2000.0315. Neurobiol Dis. 2000. PMID: 11114259
-
Multiple sclerosis and Alzheimer's disease.Ann Neurol. 2008 Feb;63(2):174-83. doi: 10.1002/ana.21240. Ann Neurol. 2008. PMID: 17924575
-
Therapy of X-linked adrenoleukodystrophy.Expert Rev Neurother. 2008 Sep;8(9):1367-79. doi: 10.1586/14737175.8.9.1367. Expert Rev Neurother. 2008. PMID: 18759549 Review.
-
Gene therapy strategies for X-linked adrenoleukodystrophy.Curr Opin Mol Ther. 2001 Aug;3(4):357-61. Curr Opin Mol Ther. 2001. PMID: 11525559 Review.
Cited by
-
Redox interplay between mitochondria and peroxisomes.Front Cell Dev Biol. 2015 May 27;3:35. doi: 10.3389/fcell.2015.00035. eCollection 2015. Front Cell Dev Biol. 2015. PMID: 26075204 Free PMC article. Review.
-
A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.Endocrinology. 2017 May 1;158(5):1328-1338. doi: 10.1210/en.2016-1842. Endocrinology. 2017. PMID: 28200172 Free PMC article.
-
Pathophysiology of X-linked adrenoleukodystrophy.Biochimie. 2014 Mar;98(100):135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. Biochimie. 2014. PMID: 24316281 Free PMC article. Review.
-
Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy.Acta Neuropathol Commun. 2023 Jun 18;11(1):98. doi: 10.1186/s40478-023-01595-w. Acta Neuropathol Commun. 2023. PMID: 37331971 Free PMC article.
-
Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy.Genes (Basel). 2025 May 17;16(5):590. doi: 10.3390/genes16050590. Genes (Basel). 2025. PMID: 40428412 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical